AI Terminal
Zealand Pharma
Share Issue/Capital Change • Jun 3, 2019
3391_dirs_2019-06-03_a100edb7-87f9-4533-b03b-53ef30885c36.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Total number of shares and voting rights in Zealand Pharma as of May 31, 2019
Total number of shares and voting rights in Zealand Pharma as of May 31, 2019
Company announcement – No. 18 / 2019
Total number of shares and voting rights in Zealand Pharma as of May 31, 2019
Copenhagen, June 3, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Consolidated Act no. 12 of 8 January 2018 on capital markets, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcements No. 12/2019 of April 5, 2019 and No. 17/2019 of May 28, 2019, Zealand announced increases in its share capital after exercise of warrants. Following the announcements, the table below lists the total number of shares and voting rights in Zealand up to and including May 31, 2019:
| Date | Number of shares (nominal value of DKK 1 each) |
Share capital (nominal value in DKK) |
Number of voting rights |
| May 31, 2019 | 31,725,475 | 31,725,475 | 31,725,475 |
For further information, please contact:
Emmanuel Dulac, President and Chief Executive Officer
Tel.: +45 50 60 36 36, e-mail: [email protected]
Lani Pollworth Morvan, Investor Relations and Communication
Tel.: +45 50 60 37 78, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment